Speaker Profile
CEO, Co-founder, Earli
Biography
Cyriac Roeding is an American-German serial entrepreneur and investor in Silicon Valley focused on the intersection of physical and digital worlds. Earli is his fourth company, a BioAI firm that turns cancer cells against themselves with intravenously injected genetic switches that only activate in cancer cells and reprogram them to activate the immune system against themselves. It raised $104M from a16z, Khosla, Perceptive, Alex Gorsky (former CEO JJ) and others. Its SAB includes Jim Allison (Nobel Laureate) and Bob Langer. Roedings prior startup Shopkick was acquired for $250M, producing an 11x return for lead investor Kleiner Perkins. He is invested in 20 startups including OpenAI and VCs (a16z, Founders Fund, Greylock). Cyriac sold his first computer program in Germany at age 15, coded for HP during high school, and studied Japanese Management in Tokyo. At 25 at Mc Kinsey, he co-authored the Harvard Business Press book Secrets-of-Software-Success. The World Economic Forum named him Global Innovator.
Talk
What if on-targetoff-tumor effects were much less of a concern in the future for cancer treatments? With higher doses possible, drug efficacy would increase substantially. This talk is about systemically injected new "synthetic genetic switches" that turn on only in cancer cells, reprogramming them to produce their own immunotherapy, from TCEs to cytokines to multi-specifics.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
